Clinical Infectious Diseases AI Policy: ChatGPT and Generative AI Disclosure Rules for CID Authors
Clinical Infectious Diseases (Oxford University Press) requires AI disclosure under the publisher rules. AI cannot be an author. This guide covers where to disclose, what to disclose, and the consequences of non-compliance for CID submissions.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
Clinical Infectious Diseases at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- IF 8.3 puts Clinical Infectious Diseases in a visible tier, citations from papers here carry real weight.
- Scope specificity matters more than impact factor for most manuscript decisions.
- Acceptance rate of ~25-35% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope, borderline fit rarely improves after submission.
- If timeline matters: Clinical Infectious Diseases takes ~90-120 days median. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
Quick answer: The Clinical Infectious Diseases AI policy follows the publisher's rules calibrated to practice-changing infectious-disease research submissions.
AI tools can be used for manuscript preparation but substantive generative-AI use must be disclosed in the location the publisher requires; basic copy editing may be treated differently, with CID's editorial team checking specifics during submission screening or review.
AI cannot be listed as an author of any CID paper. AI-generated figures and schematics representing original research data are prohibited under CID's image-integrity standard. Clinical Infectious Diseases (Oxford University Press) editors can treat undisclosed substantive AI use as a publication-ethics problem, with the response depending on the publisher policy, the timing, and whether the scientific record is affected.
Run the CID submission readiness check which includes an automated AI-disclosure audit, or work through this guide manually. Need broader context? See the CID journal overview.
The Manusights CID readiness scan. This guide tells you what Clinical Infectious Diseases (Oxford University Press)'s editors look for when verifying AI disclosure at desk-screen. The scan tells you whether your manuscript has the disclosure language required by the current journal policy before you submit.
We have reviewed manuscripts targeting Clinical Infectious Diseases (Oxford University Press) and peer venues; the named patterns below are patterns we check against the publisher's public AI policy and common editorial-screening risks. 60-day money-back guarantee. We do not train AI on your manuscript and delete it within 24 hours.
Editorial detail (for desk-screen calibration). Verify the current Editor-in-Chief and handling-editor list on the journal's editorial-team page before quoting any name in a submission cover letter. Submission portal: ScholarOne submission portal. Manuscript constraints: 250-word abstract limit and 3,500-word main-text cap (CID enforces during desk-screen).
We reviewed the publisher's AI policy framework against current CID author guidelines (accessed 2026-05-08); evidence basis includes both publicly documented the publisher policy and our internal anonymized submission corpus. The applicable word limit at CID is shown below: 250-word abstract limit and 3,500-word main-text cap (CID enforces during desk-screen).
Verify exact word and figure limits against the latest author guidelines before submission. The named editorial-culture quirk: CID editors enforce practice-changing-evidence threshold; mechanism-only papers without immediate clinical-translation pathway extend revision.
What does Clinical Infectious Diseases (Oxford University Press)'s AI policy require?
CID authors should check four policy areas under the publisher's current AI framework before submission:
Rule 1: Disclose every AI tool used in manuscript preparation
Authors should document substantive generative-AI use with the tool name, version or access date, and how it was used. Use the disclosure location specified by the current publisher policy, often Methods or a dedicated AI-use statement, rather than burying it in the cover letter. Examples that REQUIRE disclosure at CID:
- For CID-targeted manuscripts addressing practice-changing infectious-disease research: using ChatGPT, Claude, Gemini, or similar to draft, polish, or edit manuscript text passing through CID editorial review
- For CID submissions: using AI to generate boilerplate text for limitations, ethics statements, or CID-specific response-to-reviewers letters that cite the publisher's framework
- For Clinical Infectious Diseases (Oxford University Press) submissions: using AI to translate manuscript text into English from another language, with the publisher expecting disclosure of the source language and translation chain
- For CID literature reviews: using AI for citation discovery or summarizing prior CID work; the publisher's policy applies regardless of citation context
- For CID analytical pipelines: AI-assisted code generation requires Methods or code disclosure under the current publisher policy, particularly when code affects analysis
Examples that do NOT require AI disclosure:
- At CID, using grammar/spell checkers (Word) for line-level edits, when used without generative AI features for new manuscript content
- For CID submissions, using reference managers (Zotero, EndNote) for citation formatting against the publisher's style guide
- For Clinical Infectious Diseases (Oxford University Press) statistical analysis, using established statistical software (R, Stata, SPSS) where the algorithm is the established tool documented in CID's methodological norm, not a generative AI
Rule 2: AI cannot be an author
No AI tool can be listed as an author of a CID paper, particularly for practice-changing infectious-disease research-class submissions. Under the publisher's policy: authorship requires the ability to take responsibility for the content, agree to be accountable for accuracy, and to consent to publication. AI tools cannot do any of these in CID's editorial framework. This rule is consistent across all the publisher-published journals and applied at CID's desk-screen.
Rule 3: AI-generated figures are prohibited for original research data
Clinical Infectious Diseases (Oxford University Press) editorial team does not accept AI-generated images, figures, or schematics that represent original research data in practice-changing infectious-disease research-class submissions. AI tools may assist with figure layout (axis labeling, color schemes) but the underlying data visualization must come from the actual research. AI-generated diagrams used for conceptual illustrations (e.g., a schematic of a hypothesized mechanism) require explicit disclosure and a statement that the diagram is conceptual.
Rule 4: Disclose AI use in peer review participation
Reviewer AI-use rules are publisher-specific and can change quickly. Reviewers must follow the journal's confidentiality and AI-use policy; authors should not assume that reviewer-side AI rules are identical across journals in the same portfolio.
How does Clinical Infectious Diseases (Oxford University Press)'s AI policy compare to peer journals?
Rule | CID stance | the publisher default | Policy basis |
|---|---|---|---|
AI authorship | Prohibited | Prohibited | Authorship/accountability |
Disclosure location | Methods section | Methods section | Authorship/accountability |
AI-generated figures | Prohibited for original data | Prohibited | Image-integrity guidance |
Reviewer AI use | Disclosure required | Disclosure required | Peer-review confidentiality guidance |
Enforcement intensity | Desk-screen check | Desk-screen check | Submission-stage policy check |
Source: (accessed 2026-05-08) plus CID author guidelines.
What does AI disclosure look like in a CID Methods section?
Acceptable disclosure language for CID submissions:
"For our practice-changing infectious-disease research-focused manuscript at CID, we used ChatGPT-4o (OpenAI, version dated October 2024) to polish English-language phrasing in the Introduction and Discussion sections. We did not use generative AI for data analysis, figure generation, or substantive manuscript content. All authors reviewed and edited the AI-assisted text and take responsibility for the final manuscript."
Or, for AI-assisted code:
"For this CID submission addressing practice-changing infectious-disease research, initial Python code for the Bayesian regression analysis was drafted with Claude 3.5 Sonnet (Anthropic, version dated December 2024). All code was reviewed, modified, and validated by the authors before use; the final version is available at [repository URL]. Statistical inference was performed using the established R package brms."
What does NOT pass CID's desk-screen:
- For CID addressing practice-changing infectious-disease research: "AI tools were used in manuscript preparation." Too vague for the publisher editorial review of CID submissions; the CID editorial team needs the specific tool name, version, and specific use case
- "We acknowledge AI assistance in the Acknowledgments." (Do not rely on this location unless the current journal policy explicitly allows it.)
- "ChatGPT helped write this paper." (Insufficient detail on use case)
- No disclosure when AI was used (publication-ethics violation)
Desk-screen risks we see before submission
For CID-targeted manuscripts, the patterns below are common AI-policy risk areas to check against the publisher's current guidance before submission. Of the manuscripts we screened in 2025 targeting CID and peer venues, the patterns below are the same ones the journal's editorial AI committee flags during editorial review.
AI disclosure missing despite obvious AI-assisted phrasing. Substantive AI-assisted drafting without a required disclosure can trigger an editorial query. Check whether your manuscript reads as AI-assisted
AI disclosure placed in the wrong manuscript location. CID editorial team flags this as a common mistake against practice-changing infectious-disease research submissions. Publisher policies differ on whether AI disclosure belongs in Methods, a dedicated AI-use statement, acknowledgments, or another manuscript section. A misplaced disclosure can create an avoidable submission query. Check whether your AI disclosure is in the right section
Generic disclosure language without tool name and version. CID editorial team requires the specific tool, its version (or access date), and the specific use case. "AI tools were used" without specifics gets returned. Check whether your AI disclosure has the required specificity
What is the CID AI-policy compliance timeline?
Stage | Duration | What happens |
|---|---|---|
Author drafts AI disclosure | 30-60 minutes | Identify all AI use, gather tool versions, write Methods paragraph |
Co-author review of disclosure | 1-2 days | All authors confirm the disclosure is complete and accurate |
Editorial desk-screen check | 1-2 weeks | CID's editorial team checks the disclosure against the manuscript when policy review is triggered |
Editorial query (if disclosure incomplete) | 5-10 days | Editor requests revision before sending to peer review |
Reviewer AI-disclosure check | During peer review | Reviewers verify the disclosure matches the manuscript style |
Source: Manusights internal review of CID-targeted submissions, 2025 cohort.
Submit If
- For Clinical Infectious Diseases (Oxford University Press) submissions on practice-changing infectious-disease research: the manuscript documents substantive generative-AI use with the tool name, version or access date, specific use case, and disclosure location required by the current journal policy
- For CID: no AI tool is listed as an author; all listed authors meet authorship criteria and take responsibility for the final manuscript
- For Clinical Infectious Diseases (Oxford University Press): figures and schematics representing original research data come from the actual research, with any AI-assisted image or figure workflow checked against the current journal image policy
- For CID submissions: the disclosure makes clear that human authors reviewed the AI-assisted material and take responsibility for the final manuscript
Readiness check
Run the scan while the topic is in front of you.
See score, top issues, and journal-fit signals before you submit.
Think Twice If
- The manuscript contains substantive AI-assisted drafting but no disclosure; this can trigger an editorial query if the journal requires disclosure for that use case.
- The AI disclosure is placed in a section the current journal policy does not recognize.
- The disclosure language is generic without naming the tool, version or access date, and use case; journals may query or return manuscripts with this gap.
- Any figure, schematic, or image workflow used generative AI without being checked against the current journal image policy.
Manusights submission-corpus signal for Clinical Infectious Diseases (Oxford University Press).
Of the manuscripts our team screened before submission to CID and peer venues in 2025, the AI-policy compliance gap most consistent across the cohort is generic disclosure language without tool-version specificity. In our analysis of anonymized CID-targeted submissions, manuscripts with complete AI disclosure (tool name, version, specific use case, all-author confirmation) clear desk-screen at the same rate as manuscripts without AI use; manuscripts with incomplete or missing disclosure trigger editorial queries that add 1-2 weeks to the timeline.
Clinical Infectious Diseases (Oxford University Press) follows the publisher's public AI policy, but authors should verify the current journal page before submission because AI-use rules, disclosure locations, and image guidance continue to change.
What can CID authors do to stay ahead of AI policy changes?
The publisher's AI policy framework continues to evolve as 2026 brings new ICMJE recommendations, COPE guidance refinements, and journal-specific clarifications. CID authors targeting practice-changing infectious-disease research submissions should track three signals throughout 2026:
Quarterly policy updates from the publisher. the journal's editorial AI committee reviews the AI framework on a rolling basis. CID authors who pre-register their disclosure language at submission time tend to face fewer revisions during the 2026 transition period than authors who write boilerplate disclosures.
Field-specific clarifications for practice-changing infectious-disease research. Different research domains see different AI use patterns. CID's editorial team has been refining what counts as "substantive AI use" versus "ancillary AI assistance" for practice-changing infectious-disease research work. Authors who err on the side of more disclosure rather than less avoid the publication-ethics gray zone.
Reviewer disclosure norms. As the publisher extends AI-disclosure rules to peer reviewers, the response rate from CID reviewers may shift. Authors should expect that CID reviewers' use of AI tools is now also disclosed and factored into editorial decisions.
- Manusights internal preview corpus (2025 cohort)
Competitor pricing and feature claims on this page reflect publicly listed information as of 2026-05-14. Pricing and features may change; verify against each vendor's current product page before decision-making.
Frequently asked questions
Yes, with policy-required disclosure. Clinical Infectious Diseases (Oxford University Press) follows the publisher's current AI policy and broader publication-ethics guidance. AI tools can be used for language editing, manuscript preparation, and analysis support, but substantive generative-AI use must be disclosed in the location the publisher requires; basic copy editing may be treated differently. AI cannot be listed as an author, and human authors bear full responsibility for the content.
Use the disclosure location required by the current journal policy. For substantive generative-AI use, name the tool, version or access date, and use case, and make clear that human authors reviewed the final content. The journal may check this during submission screening, peer review, or production.
No. Clinical Infectious Diseases (Oxford University Press) prohibits AI-generated figures, schematics, and images intended to represent original research data. AI tools may assist with figure layout and labeling, but the underlying data and visualizations must come from the actual research. This rule is part of the publisher's broader image-integrity policy.
CID can treat undisclosed substantive AI use as a publication-ethics problem. The response depends on the publisher policy, the timing, and whether the scientific record is affected.
The shared publisher-level policy usually covers AI authorship, disclosure, and image or figure restrictions. Journal-specific guidance can differ in disclosure location, article-type expectations, and how the policy is checked during screening.
Sources
- [the publisher AI policy] (accessed 2026-05-08)
- CID author guidelines (accessed 2026-05-08)
- ICMJE recommendations on AI use (accessed 2026-05-08)
- COPE guidance on AI in research publication (accessed 2026-05-08)
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Same journal, next question
- Clinical Infectious Diseases Submission Guide: Scope, Format & Tips
- How to Avoid Desk Rejection at Clinical Infectious Diseases
- Is Clinical Infectious Diseases a Good Journal? Impact, Scope, and Fit
- Clinical Infectious Diseases Response to Reviewers: How to Write a Rebuttal That Wins (2026)
- Rejected from Clinical Infectious Diseases? The 7 Best Journals to Submit Next
- Clinical Infectious Diseases 'Under Review': What Each Status Means and When to Expect a Decision